Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Status: | Recruiting |
---|---|
Conditions: | Hematology |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | Any |
Updated: | 2/28/2019 |
Start Date: | June 2013 |
Contact: | Cristina de Min, MD |
Email: | cdemin@novimmune.com |
Phone: | +41 61 201 1322 |
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
International, multicenter, long-term, follow-up study that will enroll HLH patients who have
received NI-0501 in a previous clinical trial, in the context of the clinical development
program for NI-0501
received NI-0501 in a previous clinical trial, in the context of the clinical development
program for NI-0501
The aim of this study is to monitor the long-term safety profile of patients who have
previously received at least one dose of NI-0501, including survival at several time points
after the administration of NI-0501.
Moreover to study the elimination profile of NI-0501 and to assess the immunogenicity of
NI-0501.
Furthermore in the event that patients, upon request of the treating physician, will be
maintained on NI-0501 treatment beyond the foreseen 8 weeks, NI-0501 safety, tolerability,
efficacy and PK profile will be closely monitored in these patients until treatment
discontinuation.
previously received at least one dose of NI-0501, including survival at several time points
after the administration of NI-0501.
Moreover to study the elimination profile of NI-0501 and to assess the immunogenicity of
NI-0501.
Furthermore in the event that patients, upon request of the treating physician, will be
maintained on NI-0501 treatment beyond the foreseen 8 weeks, NI-0501 safety, tolerability,
efficacy and PK profile will be closely monitored in these patients until treatment
discontinuation.
Inclusion Criteria:
- Having received at least one dose of NI-0501.
- Having signed the Informed Consent by the patient or the patient's legal
representative(s), as applicable, with the assent of patients who are legally capable
of providing it.
Exclusion Criteria:
We found this trial at
9
sites
Cincinnati, Ohio 45229
Principal Investigator: Michael Jordan, MD
Phone: 513-636-7287
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Kimberly Kasow, MD
Phone: 919-962-8733
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
Click here to add this to my saved trials
1405 Clifton Road NE
Atlanta, Georgia 30322
Atlanta, Georgia 30322
404-785-6000
Principal Investigator: Shanmuganathan Chandrakasan, MD
Phone: 404-727-8877
Children's Healthcare of Atlanta Whether treating a toddler in an emergency or supporting a teen...
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Timothy Garrington, MD
Phone: 720-777-6740
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Barbara A Degar, MD
Phone: 617-632-5186
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Carl Allen, MD, PhD
Phone: 832-824-4312
Click here to add this to my saved trials
Münster, 48149
Principal Investigator: Claudia Rössig, Prof. Dr. Med.
Phone: 0049 2518347742
Click here to add this to my saved trials
Salt Lake City, Utah 84143
Principal Investigator: Mark N Fluchel, MD
Phone: 801-662-4710
Click here to add this to my saved trials
Wilmington, Delaware 19803
Principal Investigator: Jonathan Powell, MD
Phone: 302-651-5500
Click here to add this to my saved trials